Supernus appoints Bethany L. Sensenig to Board of Directors

SUPERNUS PHARMACEUTICALS, INC.

Ms. Sensenig appointed as independent director and Audit Committee member effective August 17, 2023.
2023 compensation: $62,500 prorated for service plus options to buy 24,153 shares at $30.22 (4-year vest).
Board expands to seven members; Ms. Sensenig brings 20+ years pharma/biotech financial leadership.
Former CFO/Interim CEO of 9 Meters Biopharma and VP Finance & Commercial Ops at Biogen.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Bethany L. Sensenig

member of the Board of Directors

SUPN · SUPERNUS PHARMACEUTICALS, INC.

Effective: 2023-08-17
Filed: August 21, 2023, 7:59 PM ET

As of August 17, 2023, the Board of Directors of Supernus Pharmaceuticals, Inc. (the “Company”) appointed Bethany L. Sensenig as a member of the Board of Directors of the Company and as a member of the Audit Committee.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Bethany L. Sensenig was appointed as member of the Board of Directors at SUPERNUS PHARMACEUTICALS, INC..

Action: appointed
Role: member of the Board of Directors

Exact text from the filing

As of August 17, 2023, the Board of Directors of Supernus Pharmaceuticals, Inc. (the “Company”) appointed Bethany L. Sensenig as a member of the Board of Directors of the Company and as a member of the Audit Committee.

View on SEC.gov

SUPERNUS PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001356576-23-000056

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.